Table 8.
Clinical trials that used combination of whole cell vaccine GVAX and chemotherapy.
| Intervention | Strategy | Date (last updated) | Status | Patient population | Phase | Results | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|---|---|
| GVAX + Adjuvant standard of care chemoradiation. | Whole-cell vaccine, Cytotoxic drugs | 17 July 2015 | Completed | 60 patients with resected stage I or II pancreatic adenocarcinoma | II | Overall survival – 24.8 months. Disease-free survival – 17.3 months |
NCT00084383 |
| GVAX + Cyclophosphamide + Cetuximab | Whole-cell vaccine, Cytotoxic drugs | 18 June 2015 | Completed | 60 patients with metastatic or locally advanced pancreatic cancer | II | Total serious adverse events – 12/60 (20%) | NCT00305760 |
| GVAX + Cyclophosphamide. | Whole-cell vaccine, Cytotoxic drugs | 17 November 2105 | Ongoing not recruiting | Stage I or II pancreatic cancer | Pilot | Combination versus GVAX monotherapy. | NCT00727441 |
| GVAX + Cyclophosphamide + SBRT + FOLFIRINOX | Whole-cell vaccine, Cytotoxic drugs, Radiation | 27 July 2015 | Ongoing not recruiting | Pancreatic cancer | Pilot | Arm 1 - SBRT + FOLFIRINOX. Arm 2 - Combination therapy |
NCT01595321 |